| Circulating tumor cells, disease progression, and survival in metastatic breast cancer M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, J Matera, MC Miller, ... New England Journal of Medicine 351 (8), 781-791, 2004 | 5292 | 2004 |
| Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer C Liedtke, C Mazouni, KR Hess, F André, A Tordai, JA Mejia, ... Journal of clinical oncology 26 (8), 1275-1281, 2008 | 3627 | 2008 |
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy R Rouzier, CM Perou, WF Symmans, N Ibrahim, M Cristofanilli, ... Clinical cancer research 11 (16), 5678-5685, 2005 | 2562 | 2005 |
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous … M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ... The Lancet Oncology 17 (4), 425-439, 2016 | 1741 | 2016 |
| Palbociclib in hormone-receptor–positive advanced breast cancer NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ... New England Journal of Medicine 373 (3), 209-219, 2015 | 1673 | 2015 |
| Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system S Riethdorf, H Fritsche, V Müller, T Rau, C Schindlbeck, B Rack, ... Clinical cancer research 13 (3), 920-928, 2007 | 1563 | 2007 |
| Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in … AU Buzdar, NK Ibrahim, D Francis, DJ Booser, ES Thomas, RL Theriault, ... Journal of clinical oncology 23 (16), 3676-3685, 2005 | 1488 | 2005 |
| Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer M Cristofanilli, DF Hayes, GT Budd, MJ Ellis, A Stopeck, JM Reuben, ... Journal of clinical oncology 23 (7), 1420-1430, 2005 | 1362 | 2005 |
| Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival DF Hayes, M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, MC Miller, ... Clinical Cancer Research 12 (14), 4218-4224, 2006 | 1218 | 2006 |
| Circulating tumor cells in patients with breast cancer dormancy S Meng, D Tripathy, EP Frenkel, S Shete, EZ Naftalis, JF Huth, PD Beitsch, ... Clinical cancer research 10 (24), 8152-8162, 2004 | 1146 | 2004 |
| Overall survival with palbociclib and fulvestrant in advanced breast cancer NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ... New England journal of medicine 379 (20), 1926-1936, 2018 | 1035 | 2018 |
| Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer GT Budd, M Cristofanilli, MJ Ellis, A Stopeck, E Borden, MC Miller, ... Clinical Cancer Research 12 (21), 6403-6409, 2006 | 967 | 2006 |
| Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification AD Seidman, MN Fornier, FJ Esteva, L Tan, S Kaptain, A Bach, ... Journal of Clinical Oncology 19 (10), 2587-2595, 2001 | 755 | 2001 |
| Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer FJ Esteva, V Valero, D Booser, LT Guerra, JL Murray, L Pusztai, ... Journal of Clinical Oncology 20 (7), 1800-1808, 2002 | 746 | 2002 |
| Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors V Guarneri, K Broglio, SW Kau, M Cristofanilli, AU Buzdar, V Valero, ... Journal of clinical oncology 24 (7), 1037-1044, 2006 | 739 | 2006 |
| Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. C Fribbens, B O'Leary, L Kilburn, S Hrebien, I Garcia-Murillas, M Beaney, ... | 698 | 2016 |
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014 | 677 | 2014 |
| Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer M Kaufmann, G Von Minckwitz, EP Mamounas, D Cameron, LA Carey, ... Annals of surgical oncology 19, 1508-1516, 2012 | 568 | 2012 |
| International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment S Dawood, SD Merajver, P Viens, PB Vermeulen, SM Swain, TA Buchholz, ... Annals of oncology 22 (3), 515-523, 2011 | 547 | 2011 |
| Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks MC Green, AU Buzdar, T Smith, NK Ibrahim, V Valero, MF Rosales, ... Journal of Clinical Oncology 23 (25), 5983-5992, 2005 | 509 | 2005 |
